Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Gene therapy: therapeutic gene causing lymphoma.

Niels-Bjarne Woods1, Virginie Bottero, Manfred Schmidt

  • 1Laboratory of Genetics, The Salk Institute for Biological Studies, La Jolla, California 92037, USA.

Nature
|April 28, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The German National Strategy for Gene- and Cell-Based Therapies: Generating Impact by Employing a Novel Multi-Stakeholder Approach.

Human gene therapy·2026
Same author

From Idea to Data: An Agentic Architecture for the Clinical Trial Life Cycle.

Studies in health technology and informatics·2026
Same author

LLM-Assisted Clinical Data Harmonization: Combining Automated ETL Generation with Semantic Vocabulary Mapping for OMOP CDM.

Studies in health technology and informatics·2026
Same author

Interpretable Feature Extraction from Clinical Notes for Sepsis Prediction: Comparing Rule-Based, LLM, and Hybrid Approaches.

Studies in health technology and informatics·2026
Same author

OMOP Extraction of Medical Text Using LLMs: Preliminary Results.

Studies in health technology and informatics·2026
Same author

Bridging Theory and Practice: A Matrix-Based Approach to Teaching Medical Data Science with MIMIC-IV Demo Dataset.

Studies in health technology and informatics·2026

Gene therapy for X-linked severe combined immune deficiency (X-SCID) using the IL2RG gene may pose risks. Studies show the therapeutic gene itself can contribute to T-cell lymphoma development in mouse models.

Area of Science:

  • Immunology
  • Gene Therapy
  • Oncology

Background:

  • Gene therapy using hematopoietic stem cells has shown promise for treating X-linked severe combined immune deficiency (X-SCID).
  • However, recent trials have seen the development of T-cell leukemia in treated patients, prompting a re-evaluation of the safety of this approach.

Purpose of the Study:

  • To investigate the potential oncogenic role of the IL2RG gene, the corrective therapeutic gene used in X-SCID gene therapy.
  • To assess the risk of T-cell lymphoma development associated with IL2RG gene therapy in a preclinical model.

Main Methods:

  • A mouse model was utilized to simulate gene therapy for X-SCID.
  • The study focused on the impact of the IL2RG gene as a therapeutic agent.

Related Experiment Videos

Main Results:

  • The IL2RG gene was found to contribute to the development of T-cell lymphomas in a significant portion (one-third) of the treated animals.
  • This finding challenges the previous assumption of IL2RG being minimally oncogenic.

Conclusions:

  • Gene therapy for X-SCID utilizing the IL2RG gene may carry an inherent risk of inducing T-cell lymphomas.
  • These findings necessitate a careful re-evaluation of the safety protocols and risk-benefit analysis for X-SCID gene therapy trials.